{
    "nct_id": "NCT02005991",
    "title": "A Phase 1, Open-Label Study To Evaluate 5-HT2a Receptor Occupancy As Measured By Positron Emission Tomography (PET) With Ligand [11C]MDL100907 Following Single Oral Dose Administration Of PP-05212377 (SAM-760) In Healthy Subjects",
    "status": "COMPLETED",
    "last_update_time": "2014-04-15",
    "description_brief": "This study will see how PF-05212377, an experimental drug to treat symptoms from Alzheimer's Disease, distributes in the brain after one dose of PF-05212377 is administered orally to healthy volunteer subjects. The study will also evaluate the safety and tolerability of PF-05212377 in these subjects and will measure the level of PF-05212377 in the blood.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE1"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "BASIC_SCIENCE",
    "results": null,
    "target_category": "Cognitive enhancer",
    "drug": [
        "PF-05212377 (SAM-760) \u2014 small\u2011molecule 5\u2011HT6 receptor antagonist"
    ],
    "placebo": [],
    "explanation_target": [
        "Reason: The trial drug PF-05212377 (SAM\u2011760) is a small\u2011molecule serotonin receptor antagonist developed to treat symptoms of Alzheimer\u2019s disease (symptomatic/cognitive benefit), not an anti\u2011amyloid or anti\u2011tau biologic. Evidence identifies PF\u201105212377 as a selective 5\u2011HT6 receptor antagonist (small molecule) investigated for symptomatic cognitive effects in AD. \ue200cite\ue202turn2view0\ue202turn2view1\ue201",
        "Act: Key details extracted from web sources \u2014 PF\u201105212377 = SAM\u2011760; mechanism = potent, selective 5\u2011HT6 receptor antagonist; developed by Pfizer for symptomatic treatment (cognition/neuropsychiatric symptoms) in AD and tested in Phase 1/2 trials. One Phase 2 study used ADAS\u2011Cog as a primary cognitive endpoint while other studies targeted neuropsychiatric symptoms as secondary/co\u2011primary outcomes. \ue200cite\ue202turn2view0\ue202turn2view1\ue202turn0search2\ue201",
        "Note on trial text discrepancy: The user\u2019s trial title/record references 5\u2011HT2A receptor occupancy using [11C]MDL100907 (a 5\u2011HT2A ligand) for PET; the clinical entry for the single\u2011dose PET occupancy study (NCT02005991) lists a 5\u2011HT2A occupancy measure, but the broader literature and later PET work describe PF\u201105212377 target engagement at 5\u2011HT6 receptors. This appears to be a protocol/registry labeling inconsistency \u2014 the drug\u2019s known pharmacology is 5\u2011HT6 antagonism. \ue200cite\ue202turn1view1\ue202turn2view0\ue201",
        "Reflect: Classification rationale \u2014 Because PF\u201105212377 is a small\u2011molecule 5\u2011HT6 receptor antagonist intended to provide symptomatic benefit (cognitive enhancement and amelioration of behavioural symptoms) rather than to modify Alzheimer\u2019s pathology (amyloid/tau) and it is not a biologic, the best fit among the provided categories is 'Cognitive enhancer' (non\u2011pathology symptomatic cognitive improvement). The drug has also been evaluated for neuropsychiatric symptom effects in trials, so there is overlap with 'neuropsychiatric symptom improvement', but primary development and cognitive endpoints (ADAS\u2011Cog) support classification as a cognitive enhancer. \ue200cite\ue202turn2view1\ue202turn0search7\ue201"
    ],
    "agent_type": "D) Neurotransmitter Receptors",
    "explanation_agent": [
        "Reason: The investigational drug PF-05212377 (SAM-760) is a small\u2011molecule antagonist of a serotonin G\u2011protein\u2011coupled receptor (5\u2011HT6) intended to produce symptomatic cognitive/neuropsychiatric benefit (a neurotransmitter\u2011receptor mechanism), not a disease\u2011modifying anti\u2011amyloid or anti\u2011tau therapy. \ue200cite\ue202turn0search5\ue202turn0search2\ue201",
        "Act: Key evidence \u2014 PF\u201105212377 (SAM\u2011760) is described as a potent, selective 5\u2011HT6 receptor antagonist developed for symptomatic treatment in Alzheimer\u2019s disease (Phase 1/2 clinical evaluation). A Phase 2 trial evaluated SAM\u2011760 30 mg QD for cognitive/neuropsychiatric outcomes in AD. The PET ligand mentioned in the trial title, [11C]MDL100907, is a selective 5\u2011HT2A radioligand (indicating a registry/protocol labeling discrepancy between the PET measure and the drug\u2019s known target). \ue200cite\ue202turn0search4\ue202turn0search6\ue202turn0search3\ue201",
        "Reflect: Classification rationale \u2014 Given the drug\u2019s primary mechanism (antagonism of a serotonin receptor to enhance cognition/behaviour), the most specific CADRO category is D) Neurotransmitter Receptors. This fits because the intervention modulates neurotransmitter receptor signaling (5\u2011HT6) rather than targeting amyloid, tau, inflammation, metabolism, vasculature, or other CADRO domains. The PET ligand/occupancy note (5\u2011HT2A) is an observational/measurement detail and does not change the drug\u2019s 5\u2011HT6 receptor classification. \ue200cite\ue202turn0search5\ue202turn0search3\ue201",
        "Web search sources used (for transparency): 1) ALZFORUM therapeutic page for PF\u201105212377 / SAM\u2011760 (drug identity, target, development history). \ue200cite\ue202turn0search5\ue201 2) Sigma\u2011Aldrich product description summarizing PF\u201105212377 as a high\u2011affinity selective 5\u2011HT6 antagonist. \ue200cite\ue202turn0search2\ue201 3) Therapeutic Target Database entry listing PF\u201105212377 target = 5\u2011HT6 (HTR6) and antagonist action. \ue200cite\ue202turn0search4\ue201 4) PubMed abstract of the Phase 2 clinical trial of PF\u201105212377 (SAM\u2011760) in AD (clinical context and dosing). \ue200cite\ue202turn0search6\ue201 5) PubMed description of [11C]MDL100907 as a selective 5\u2011HT2A PET ligand (explains the PET measure referenced in the trial title). \ue200cite\ue202turn0search3\ue201"
    ]
}